TARA Protara Therapeutics Inc

$TARA I am very bullish on TARA although I don't see any major price resurgence until spring of next year, most likely.....but what a great time to accumulate now while it's beaten down. Why? Well, how many small bios have a drug in their pipelines that has proven "curative?" TARA does with TARA-002 to treat LMs. To date, all data shows a curative effect. TARA owns global rights aside from Japan and Taiwan...TARA has responsibility to develop and commercialize TARA-002 globally while Chugai retains rights within Japan and Taiwan where the originator compound, OK-432 (Picibanil) is already approved and standard care for LMs. TARA is eligible for a valuable PRV upon approval of the BLA it intends to file in the 2nd half of 2027. I believe this BLA is going to be a major catalyst and cause a major increase in TARA's market cap. JMO

$TARA getting closer to cooking something up by end of year. Historically, this ticker has had some interesting movements this time of year on the good side.

$TARA for those fretting the trading....my own opinion agrees with AI's explanation: probable catalysts behind this type of "newsless" price dislocation: • Institutional Tax-Loss Harvesting: Many mutual funds and institutional portfolios have fiscal year-ends on October 31. In the weeks leading up to this deadline, institutions frequently liquidate underperforming micro-cap positions to offset capital gains, creating severe downward pressure on high volume. • Forced Liquidation or Block Trades: In low-float, illiquid biotech stocks, a single large institutional holder exiting a position can quickly overwhelm the order book. Lacking sufficient buying liquidity, these large blocks trigger market-maker price reductions to absorb the shares. • Algorithmic and Stop-Loss Cascades: When a stock breaks through long-term psychological support levels, it often triggers systematic stop-loss orders and automated algorithmic short-selling, causing a self-reinforcing cascade of high-volume selling.

$TARA "Wall Street’s consensus rating for TARA stock is a Strong Buy, with an average analyst price target of $24.00, implying upside potential of 921.28% from current levels."

$TARA Buy now before it doubles. I’m loaded and patiently waiting for the #DATA. Let’s send it any day now.

$TARA I have been following TARA for nearly two years now. At worst, this stock is a $4 a share stock. Once news comes out about the TARA-002 bladder cancer efficacy and safety, expected in Q4, this stock could and should zoom up to close to $10 a share. This is not a pipe dream. This is as close to true statement as one can make given the data and science behind the drug. $10 a share!

$TARA this is some better movement we’ve been waiting for. Let’s put a few days of green together and claw this M’fr back!

$TARA 🤝 Protara Therapeutics, Inc. entered into an asset purchase agreement with Novex Innovations to acquire TARA-002 manufacturing-related assets for $8.75 million. Prioritized by relevance

$TARA big AI stocks down today like MU and WDC, both closed down over 17%. The Nasdaq was down over 1400 points.....S&P down 335 points....IN ONE DAY!

$TARA looks like a lot of small caps declined today as money rushed into the big name stocks. an opportunity has been created, imo....

$TARA Its been 2 weeks and e-trade still won't let me add to my position here. Is anyone else still having a problem with their brokerage?